GENERALIZED ECZEMATOUS SKIN RASH POSSIBLY DUE TO HMG-COA REDUCTASE INHIBITORS

被引:46
作者
KRASOVEC, M
ELSNER, P
BURG, G
机构
[1] Department of Dermatology, University Hospital Zurich, CH-80?1 Zurich
关键词
HMG-COA REDUCTASE INHIBITORS; SIDE EFFECTS; SKIN RASH; EPIDERMAL LIPIDS;
D O I
10.1159/000247363
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We report on 3 patients who developed a generalized eczematous skin rash under treatment with simvastatin and pravastatin for hypercholesterolemia. These drugs are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and suppress cholesterol synthesis in the liver. Based on experimental data from the literature that showed eczematous changes in mice treated topically with the HMG-CoA reductase inhibitor lovastatin, we suspect that the rash observed in our patients may be a consequence of skin barrier dysfunction following inhibition of cholesterol biosynthesis.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 13 条
[1]   COMPARISON OF DIFFERENT HMG-COA REDUCTASE INHIBITORS [J].
DITSCHUNEIT, HH ;
KUHN, K ;
DITSCHUNEIT, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 :S27-S32
[2]   THE LOVASTATIN-TREATED RODENT - A NEW MODEL OF BARRIER DISRUPTION AND EPIDERMAL HYPERPLASIA [J].
FEINGOLD, KR ;
MAOQIANG, M ;
PROKSCH, E ;
MENON, GK ;
BROWN, BE ;
ELIAS, PM .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1991, 96 (02) :201-209
[3]   CHOLESTEROL-SYNTHESIS IS REQUIRED FOR CUTANEOUS BARRIER FUNCTION IN MICE [J].
FEINGOLD, KR ;
MAN, MQ ;
MENON, GK ;
CHO, SS ;
BROWN, BE ;
ELIAS, PM .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (05) :1738-1745
[4]   EFFICACY AND SAFETY OF PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA .1. A DOSE-RESPONSE STUDY [J].
HUNNINGHAKE, DB ;
KNOPP, RH ;
SCHONFELD, G ;
GOLDBERG, AC ;
BROWN, WV ;
SCHAEFER, EJ ;
MARGOLIS, S ;
DOBS, AS ;
MELLIES, MJ ;
INSULL, W ;
STEIN, EA .
ATHEROSCLEROSIS, 1990, 85 (01) :81-89
[5]   DECREASED STRATUM-CORNEUM CERAMIDES IN ATOPIC INDIVIDUALS - A PATHO-BIOCHEMICAL FACTOR IN XEROSIS [J].
MELNIK, B ;
HOLLMANN, J ;
PLEWIG, G .
BRITISH JOURNAL OF DERMATOLOGY, 1988, 119 (04) :547-549
[6]   STRUCTURAL BASIS FOR THE BARRIER ABNORMALITY FOLLOWING INHIBITION OF HMG COA REDUCTASE IN MURINE EPIDERMIS [J].
MENON, GK ;
FEINGOLD, KR ;
MAOQIANG, M ;
SCHAUDE, M ;
ELIAS, PM .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 98 (02) :209-219
[7]   CLINICAL-PHARMACOLOGY OF PRAVASTATIN, A SELECTIVE INHIBITOR OF HMG-COA REDUCTASE [J].
PAN, HY .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 :S15-S18
[8]  
STEYN K, 1991, S AFR MED J, V79, P639
[9]  
TOBERT JA, 1986, JAMA-J AM MED ASSOC, V256, P2829
[10]   SIMVASTATIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN HYPERCHOLESTEROLEMIA [J].
TODD, PA ;
GOA, KL .
DRUGS, 1990, 40 (04) :583-607